Talacotuzumab (JNJ-56022473), a humanized anti-CD123 monoclonal antibody, showed ADCC-mediated cytotoxicity and direct inhibitory effects on IL-3-dependent tumor growth in AML xenograft murine models, but, so far, has failed to show a significant therapeutic advantage, either as a single agent or in combination with decitabine (possibly due to a lack of cell-mediated cytotoxicity in patients with advanced disease) [17]. This evidence concerns the gene IL3 and acute myeloid leukemia.